Custom Search


Monday 12 June 2006

Alexza Pharmaceuticals, Inc. (ALXA) To Present AZ-001 Phase IIa Clinical Data At The American Headache Society Meeting

By: Biospace News

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA - News) announced today that it will present at the 48th annual American Headache Society meeting the results of a Phase IIa clinical trial of Staccato(TM) Prochlorperazine (AZ-001) for the acute treatment of migraine headache.

The poster presentation, "Inhaled prochlorperazine in patients having an acute migraine attack" (Abstract F51) will be available for viewing at the meeting at the Hyatt Regency Century Plaza Hotel in Los Angeles, California on Friday, June 23, 2006 from 10:00 a.m. to 4:00 p.m. James V. Cassella, PhD, Alexza Senior Vice President, Research and Development will be presenting the poster from 12:30 p.m. to 1:30 p.m. on Friday, June 23, 2006.

Read Original Text

Use of this site is subject to the following terms of use